BSE · 531173
Syschem (India) Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹386 Cr with net profit ₹0 Cr — a 0.12% net margin, versus 1.18% the period before.
Shareholding
As of 2026-07-31
- Promoter63.38%
- Public36.47%
- DII0.15%
12,825 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.55× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #63 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 12.06% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,420 Cr | 431.06 | 2.51 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹70,215 Cr | 545.38 | 2.04 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Syschem (India) Ltd.(this company) | ₹204 Cr | 18.69 | 1.67 | 8.93% | 1.45% |
AI analysis
AI-generated · google/gemini-2.5-flashSyschem (India) Ltd. is listed on the Indian markets with a market capitalization of Rs 216 Cr. The company has a PE ratio of 19.77 and an EPS of 2.22. Its book value stands at Rs 24.9. Syschem (India) Ltd. generated a revenue of Rs 386.27 Cr and reported a profit margin of 144.8%.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +The profit margin is high at 144.8%.
- +Net profit has improved from a loss of Rs 5.57 Cr in Mar 2021 to a profit of Rs 0.46 Cr in Mar 2025.
- +Promoter holding is substantial at 63.38% as of July 31, 2026.
Negatives
- −The trailing twelve months EPS is lower at 0.109 in Mar 2025 compared to 0.78 in Mar 2024.
- −The annual net profit has declined from Rs 4.51 Cr in Mar 2023 to Rs 0.46 Cr in Mar 2025.
Financial Performance
The company's revenue increased from Rs 74.67 Cr in Mar 2021 to Rs 386.27 Cr in Mar 2025. Net profit, however, showed fluctuations, moving from a loss of Rs 5.57 Cr in Mar 2021 to a profit of Rs 0.46 Cr in Mar 2025. Annual EPS also varied, from -2.7 in Mar 2021 to 0.109 in Mar 2025. Quarterly, revenue was Rs 219.35 Cr in Mar 2026, with a net profit of Rs 1.74 Cr.
Profitability & Returns
Syschem (India) Ltd. recorded a Return on Equity (ROE) of 8.93% and a Return on Capital Employed (ROCE) of 13.60%. The profit margin for the company is 144.8%. The company reported a positive net profit of Rs 0.46 Cr for the period ending Mar 2025, a significant improvement from the net loss of Rs 5.57 Cr in Mar 2021.
Balance Sheet
The company has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 24.9. There are no reported pledges for promoter shares. The current market capitalization stands at Rs 216 Cr.
Ownership & Pledges
As of July 31, 2026, the promoter holding in Syschem (India) Ltd. was 63.38%. Public shareholding was 36.47%. DIIs held 0.15% of the shares, while FIIs held 0%. The number of shareholders as of July 31, 2026, was 12825. There were no promoter share pledges reported for the period ending July 31, 2026.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jul 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.